<?xml version='1.0' encoding='utf-8'?>
<document id="21041919"><sentence text="Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients."><entity charOffset="0-11" id="DDI-PubMed.21041919.s1.e0" text="Raltegravir" /><entity charOffset="26-36" id="DDI-PubMed.21041919.s1.e1" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.21041919.s1.e0" e2="DDI-PubMed.21041919.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21041919.s1.e0" e2="DDI-PubMed.21041919.s1.e1" /></sentence><sentence text="Because of the favourable safety and tolerability profiles of atazanavir (ATV) and raltegravir (RAL), attention has recently turned to the use of dual ATV plus RAL therapy as a nucleoside reverse transcriptase inhibitor-sparing treatment strategy in highly antiretroviral treatment (ART)-experienced HIV-infected patients"><entity charOffset="62-72" id="DDI-PubMed.21041919.s2.e0" text="atazanavir" /><entity charOffset="74-77" id="DDI-PubMed.21041919.s2.e1" text="ATV" /><entity charOffset="83-94" id="DDI-PubMed.21041919.s2.e2" text="raltegravir" /><entity charOffset="96-99" id="DDI-PubMed.21041919.s2.e3" text="RAL" /><entity charOffset="151-153" id="DDI-PubMed.21041919.s2.e4" text="ATV" /><entity charOffset="160-162" id="DDI-PubMed.21041919.s2.e5" text="RAL" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e0" e2="DDI-PubMed.21041919.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e0" e2="DDI-PubMed.21041919.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e0" e2="DDI-PubMed.21041919.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e0" e2="DDI-PubMed.21041919.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e0" e2="DDI-PubMed.21041919.s2.e4" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e0" e2="DDI-PubMed.21041919.s2.e5" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e1" e2="DDI-PubMed.21041919.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e1" e2="DDI-PubMed.21041919.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e1" e2="DDI-PubMed.21041919.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e1" e2="DDI-PubMed.21041919.s2.e4" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e1" e2="DDI-PubMed.21041919.s2.e5" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e2" e2="DDI-PubMed.21041919.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e2" e2="DDI-PubMed.21041919.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e2" e2="DDI-PubMed.21041919.s2.e4" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e2" e2="DDI-PubMed.21041919.s2.e5" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e3" e2="DDI-PubMed.21041919.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e3" e2="DDI-PubMed.21041919.s2.e4" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e3" e2="DDI-PubMed.21041919.s2.e5" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e4" e2="DDI-PubMed.21041919.s2.e4" /><pair ddi="false" e1="DDI-PubMed.21041919.s2.e4" e2="DDI-PubMed.21041919.s2.e5" /></sentence><sentence text="" /><sentence text="A retrospective observational study was carried out to assess the maintenance of viral suppression and ART tolerability in 20 highly ART-experienced patients with viral suppression, who had been switched to RAL and unboosted ATV dual therapy, using data collected during standard-of-care visits"><entity charOffset="225-227" id="DDI-PubMed.21041919.s4.e0" text="ATV" /><entity charOffset="207-209" id="DDI-PubMed.21041919.s4.e1" text="RAL" /><pair ddi="false" e1="DDI-PubMed.21041919.s4.e1" e2="DDI-PubMed.21041919.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21041919.s4.e1" e2="DDI-PubMed.21041919.s4.e0" /></sentence><sentence text="" /><sentence text="At 6, 12 and 18 months, viral load was maintained at &lt;400 HIV RNA copies/ml, with only one participant recording a detectable viral load (150 copies/ml) at the 6-month time point" /><sentence text=" Stable CD4(+) T-cell counts were maintained throughout the study period" /><sentence text=" Five participants changed regimen during the 18-month follow-up, with the median time to switch being 9 months (range 2-12)" /><sentence text=" In three cases, patients were changed from dual therapy because of adverse events while on the regimen" /><sentence text=" These included increased fatigue (two patients), persistently increased bilirubin (one patient) and gastrointestinal side effects (one patient)"><entity charOffset="73-82" id="DDI-PubMed.21041919.s10.e0" text="bilirubin" /></sentence><sentence text=" Two additional patients changed therapy: one patient added lamivudine and one ceased ATV to pre-empt a potential drug-drug interaction"><entity charOffset="60-70" id="DDI-PubMed.21041919.s11.e0" text="lamivudine" /><entity charOffset="86-95" id="DDI-PubMed.21041919.s11.e1" text="ATV" /><pair ddi="false" e1="DDI-PubMed.21041919.s11.e0" e2="DDI-PubMed.21041919.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21041919.s11.e0" e2="DDI-PubMed.21041919.s11.e1" /></sentence><sentence text=" All five patients who switched from ATV/RAL before 12 months follow-up maintained viral suppression, implying no disadvantage from switching to dual therapy"><entity charOffset="37-39" id="DDI-PubMed.21041919.s12.e0" text="ATV" /><entity charOffset="41-43" id="DDI-PubMed.21041919.s12.e1" text="RAL" /><pair ddi="false" e1="DDI-PubMed.21041919.s12.e0" e2="DDI-PubMed.21041919.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21041919.s12.e0" e2="DDI-PubMed.21041919.s12.e1" /></sentence><sentence text="" /><sentence text="Dual therapy with ATV plus RAL maintained viral suppression in this small group of highly ART-experienced patients"><entity charOffset="18-20" id="DDI-PubMed.21041919.s14.e0" text="ATV" /><entity charOffset="27-29" id="DDI-PubMed.21041919.s14.e1" text="RAL" /><pair ddi="false" e1="DDI-PubMed.21041919.s14.e0" e2="DDI-PubMed.21041919.s14.e0" /><pair ddi="false" e1="DDI-PubMed.21041919.s14.e0" e2="DDI-PubMed.21041919.s14.e1" /></sentence><sentence text=" Further investigation of this novel dual therapy regimen is warranted" /><sentence text="" /></document>